Search | IOVS | ARVO Journals

Showing 1 – 20 of 48

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Structural OCT biomarkers, trends, and early detection in fellow eyes of patients receiving Intravitreal injections for neovascular age-related macular degeneration (nAMD) over a 5-year period.

Sneha Melmane; Savithri Sreekala; Lekshmi Thankachan; Harbhajan Arora; Geeta Menon; Karima Nesnas; Manju Chandran

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):239.

ARVO Annual Meeting Abstract June 2024

A Prospective study of type 1 and type 2 Diabetics examining the correlation between antioxidant levels and neuronal layer loss. (DECAN study)

LORRAINE NORTH; Manju Chandran; Geeta Menon; Narendran Nair

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):868.

ARVO Annual Meeting Abstract June 2024

Real-world evidence of biosimilar Ranibizumab in management of neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macula oedema (DMO): Switches and treatment naive.

Petya Simeonova Ford; Geeta Menon; Sneha Melmane; Amy Mohan; Karima Nesnas; Lorraine North; Narendran Nair; Manju Chandran

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):243.

ARVO Annual Meeting Abstract June 2024

Ten-Year -Real World Outcome (RWO) of Anti Vascular Endothelial Growth Factor Therapy(Anti VEGF)in Diabetic MAcular Oedema(DMO).

Sely Mathew; Manju Chandran; Harbhajan Arora; Geeta Menon; narendran nair; aarthy Jeganathen; Mohamed Elsaeed; Amy Mohan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3214.

ARVO Annual Meeting Abstract June 2024

Towards automated optical coherence tomography (OCT) data analysis for a real-world diabetic macular edema (DME) treatment cohort

James Talks; Tunde Peto; Xiaoyong Wang; Anda Gershon; Geeta Menon; Faruque Ghanchi; Xin Chen; Vivian Look; Huanxiang Lu; Michael H. Chen; Daniela Ferrara; Gloria Chi; Qi Yang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5956.

ARVO Annual Meeting Abstract June 2024

Real-world evidence of Faricimab in management of Neovascular Age related Macular Degeneration (nAMD) and Diabetic Macular Oedema (DMO) : Treatment Naïve and Suboptimal Responders.

Savithri Sreekala; Sneha Melmane; Mohamed Elsaeed; Harbhajan Arora; Manju Chandran; Geeta Menon

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6122.

ARVO Annual Meeting Abstract June 2023

Ten Year Real World Outcome of Anti-Vascular Endothelial Growth Factor therapy in Neovascular Age-Related Macular Degeneration

Sneha Melmane; Savithri Sreekala; Manju Chandran; Geeta Menon; Sowjanya Yerramsetti

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2220.

ARVO Annual Meeting Abstract June 2023

Diabetic macular edema 5-year outcomes: a multicenter analysis

Tunde Peto; James Talks; Geeta Menon; Faruque Ghanchi; Xin Chen; Qi Yang; Daniela Ferrara; Luyi Adesanye; Gloria C Chi

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2650.

ARVO Annual Meeting Abstract June 2023

6-year outcomes of the United Kingdom Medisoft® audit study following treatment with the ILUVIEN® (fluocinolone acetonide) implant in patients with diabetic macular edema.

Bushra Mushtaq; Clare C Bailey; Usha Chakravarthy; Andrew J Lotery; James Talks; Geeta Menon

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2651.

ARVO Annual Meeting Abstract June 2021

A Prospective study of type 1 and type 2 Diabetics examining the correlation between antioxidant levels and neuronal layer loss. (DECAN study)- An exploratory Study

LORRAINE NORTH; Geeta V Menon; Manju Chandran

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1103.

ARVO Annual Meeting Abstract June 2021

Safety of multiple intravitreal injections of ocriplasmin in subjects with non–proliferative diabetic retinopathy (NPDR): Results of the CIRCLE study.

Mahi Muqit; Ramin Tadayoni; J Hamouz; Victor H Gonzalez; Javier Montero; David Scales; Geeta V Menon; Prema Abraham; Timothy L Jackson; Ivan Fiser; Petra Kozma-Wiebe

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1083.

ARVO Annual Meeting Abstract July 2019

The Application of Deep Learning System to Screen for Diabetic Retinopathy in an Underprivileged African Population with Diabetes

Valentina Bellemo; Zhan Wei Lim; Gilbert Lim; Quang Nguyen; Michelle Y.T. Yip; Yuchen Xie; Xin Qi Lee; Haslina Hamzah; Jinyi Ho; Gavin Siew Wei Tan; Wynne Hsu; Mong Li Lee; Sobha Sivaprasad; Geeta Menon; Tien Yin Wong; Daniel SW Ting

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1439.

ARVO Annual Meeting Abstract July 2018

Real world data of Anti-VEGF treatment (Aflibercept) in treatment naive Neovascular Age Related Macular Degeneration (nAMD) over 3 years

Manju Chandran; Sidharth Praveen; Lorraine North; Hasan Naveed; Leena Bhat; Sely Mathew; Narendran Nair; Geeta Menon

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):839.

ARVO Annual Meeting Abstract July 2018

United Kingdom multicenter Medisoft™ electronic medical record real-world audit following implant of ILUVIEN ® (fluocinolone acetonide 190 µg) – the first 3-year results from the UK

Fahd Quhill; Clare Bailey; Usha Chakravarthy; Andrew Lotery; Geeta Menon; James S Talks

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1906.

ARVO Annual Meeting Abstract June 2017

Clinical Features Predict Diabetic Retinopathy Progression

Cecilia S Lee; Aaron Y Lee; Doug Baughman; Atul Varma; Salim Natha; Louise Downey; Geeta Menon; Sajjad Mahmood; Usha Chakravarthy; David Paul Crabb; Alastair K Denniston; Clare Bailey; Adnan Tufail; Catherine A Egan

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4283.

ARVO Annual Meeting Abstract June 2017

UK Multi-centre Medisoft EMR audit of intra-operative pressure event following implant of ILUVIEN ® (fluocinolone acetonide 190 μg).

Fahd Quhill; Clare Bailey; Usha Chakravarthy; Andrew J Lotery; Geeta Menon; James Talks

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4622.

ARVO Annual Meeting Abstract June 2017

The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.

Serena Salvatore; Clare Bailey; Usha Chakravarthy; Andrew J Lotery; Geeta Menon; James Talks

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4631.

ARVO Annual Meeting Abstract June 2017

UK Diabetic Screening Referrals Impact on Population and Clinical Correlations

Ali S Hassan; Geeta Menon; Manju Chandran

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2905.

ARVO Annual Meeting Abstract September 2016

Efficacy of intravitreal aflibercept treatment of pigment epithelial detachment in neovascular age-related macular degeneration refractory to intravitreal ranibizumab: 2-year outcomes

Louise Ramskold; Han Bin Lee; Manju N Chandran; Petya Gencheva; Geeta Menon

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Comparsion of autofluorescence patterns in patients with myopic neovascular membrane with BCVA.

Ali Hadi AlHassany; Manju Chandran; Geeta Menon

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2703.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Structural OCT biomarkers, trends, and early detection in fellow eyes of patients receiving Intravitreal injections for neovascular age-related macular degeneration (nAMD) over a 5-year period.

A Prospective study of type 1 and type 2 Diabetics examining the correlation between antioxidant levels and neuronal layer loss. (DECAN study)

Real-world evidence of biosimilar Ranibizumab in management of neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macula oedema (DMO): Switches and treatment naive.

Ten-Year -Real World Outcome (RWO) of Anti Vascular Endothelial Growth Factor Therapy(Anti VEGF)in Diabetic MAcular Oedema(DMO).

Towards automated optical coherence tomography (OCT) data analysis for a real-world diabetic macular edema (DME) treatment cohort

Real-world evidence of Faricimab in management of Neovascular Age related Macular Degeneration (nAMD) and Diabetic Macular Oedema (DMO) : Treatment Naïve and Suboptimal Responders.

Ten Year Real World Outcome of Anti-Vascular Endothelial Growth Factor therapy in Neovascular Age-Related Macular Degeneration

Diabetic macular edema 5-year outcomes: a multicenter analysis

6-year outcomes of the United Kingdom Medisoft® audit study following treatment with the ILUVIEN® (fluocinolone acetonide) implant in patients with diabetic macular edema.

A Prospective study of type 1 and type 2 Diabetics examining the correlation between antioxidant levels and neuronal layer loss. (DECAN study)- An exploratory Study

Safety of multiple intravitreal injections of ocriplasmin in subjects with non–proliferative diabetic retinopathy (NPDR): Results of the CIRCLE study.

The Application of Deep Learning System to Screen for Diabetic Retinopathy in an Underprivileged African Population with Diabetes

Real world data of Anti-VEGF treatment (Aflibercept) in treatment naive Neovascular Age Related Macular Degeneration (nAMD) over 3 years

United Kingdom multicenter Medisoft™ electronic medical record real-world audit following implant of ILUVIEN ® (fluocinolone acetonide 190 µg) – the first 3-year results from the UK

Clinical Features Predict Diabetic Retinopathy Progression

UK Multi-centre Medisoft EMR audit of intra-operative pressure event following implant of ILUVIEN ® (fluocinolone acetonide 190 μg).

The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.

UK Diabetic Screening Referrals Impact on Population and Clinical Correlations

Efficacy of intravitreal aflibercept treatment of pigment epithelial detachment in neovascular age-related macular degeneration refractory to intravitreal ranibizumab: 2-year outcomes

Comparsion of autofluorescence patterns in patients with myopic neovascular membrane with BCVA.

To View More...

You must be signed into an individual account to use this feature.